← Back to headlines
Merck Nears $6 Billion Acquisition of Terns Pharma for Cancer Portfolio
Merck is reportedly close to a $6 billion acquisition of Terns Pharma, as reported by FT, aimed at enhancing its cancer drug pipeline following promising clinical data on a bone and blood cancer treatment.
25 Mar, 00:59 — 25 Mar, 01:14
The Story
Analyzing sources…
Source Diversity
Source Diversity
Low (24/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 1/5 buckets covered0/33
Far L
Left
Center2
Center (2)
ReutersFT
Right
Far R
Geographic diversity— 2 regions9/34
Intl1UK1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
ReutersVery High1h ago
Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports - Reuters
Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports Reuters
Read full article →FTVery High1h ago
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Read full article →Coverage Timeline
First report: FT · 25 Mar, 00:59|Full coverage: 2 · 14m|Window: 14m
Left-leaningCenterRight-leaning
Related Stories
Philippine President Marcos Declares Energy Emergency, Rolls Out Subsidies, and Eyes Joint Gas Development Amid Oil Crisis
just now
President oversees rollout of fuel subsidies
just now
Gov’t allots P20B to buy 2 million barrels of diesel
just now
Philippine Government Reduces Airport and Ro-ro Terminal Fees
just now